Parameters | Total Cohort investigated (n = 215) | ||
---|---|---|---|
Control (n = 168) | Cases (n = 47) | p value | |
Parameters on admission | |||
Age (years) | 65.5 (IQR 55.5–75.1) | 67.4 (IQR 62.4–75.9) | 0.105 |
Male gender | 75% (n = 126) | 87% (n = 41) | 0.075 |
BMI (kg/m2) | 29 (IQR 25.5–32) | 30 (IQR 26–34) | 0.499 |
SAPS | 41 (IQR 32–48) | 51 (IQR 44–59) |  < 0.001 |
Lymphcytes/nl | 0.83 (IQR 0.56–1.22) | 0.77 (IQR 0.38–1.06) | 0.112 |
Neutrophils/nl | 7.94 (IQR 5.51–11.13) | 8.14 (IQR 5.55–11.94) | 0.781 |
IL-6 (ng/l) | 110 (IQR 34.3–315.4) | 91.65 (IQR 58.3–215) | 0.868 |
CRP (mg/l) | 142.3 (IQR 68.9–234.3) | 160.8 (IQR 108.6–270.9) | 0.167 |
PCT (µg/l) | 0.38 (IQR 0.15–1.49) | 0.71 (IQR 0.22–2) | 0.169 |
Corticosteroids on admission | 8% (n = 10) | 21% (n = 24) |  < 0.001 |
Admission from external ICU | 42% (n = 71) | 21% (n = 24) | 0.283 |
ICU treatment parameters | |||
Number of microbiological samples for Aspergillus spp. | 3 (IQR 0–7) | 7 (IQR 5–11) | 0.000 |
Length of ICU stay before onset of CAPA (days) | Not applicable | 8 (IQR 4–14) | Not applicable |
Dexamethasone therapy | 76.2% (n = 128) | 87.2% (n = 41) | 0.103 |
Cortisol cumulative dose (mg) | 1.470 (390–2.670) | 900 (200–2.200) | 0.154 |
Corticosteroid treatment (days) | 7 (IQR 2–12) | 6 (IQR 2–10) | 0.298 |
Invasive ventilation (days) | 12 (IQR 1–32) | 23 (IQR 16–38) |  < 0.001 |
Days without mechanical ventilation | 1 (IQR 0–6) | 1 (IQR 0–5) | 0.171 |
Comorbidities | |||
Charlson Comorbidity Index | 5 (IQR 3–7) | 6 (IQR 5–8) | 0.015 |
Peptic ulcer | 2% (n = 4) | 4% (n = 2) | 0.490 |
Rheumatoid disease | 4% (n = 7) | 4% (n = 2) | 0.979 |
Heart disease | 24% (n = 41) | 15% (n = 7) | 0.166 |
Vascular disease | 15% (n = 25) | 17% (n = 8) | 0.719 |
Diabetes | 31% (52) | 32% (n = 15) | 0.900 |
Liver disease | 20% (n = 33) | 23% (n = 11) | 0.572 |
Renal disease | 65% (n = 109) | 87% (n = 41) | 0.003 |
Cancer | 5% (n = 9) | 11% (n = 5) | 0.195 |
AIDS/HIV | 0 (n = 0) | 0 (n = 0) | n.s |
Neurological disease | 8% (n = 14) | 6% (n = 3) | 0.661 |
Lung disease | 29% (n = 49) | 40% (n = 19) | 0.142 |